ORPHA:90285
Lupus erythematosus panniculitis
Also known as: Lupus erythematosus profundus
Publications
1,048
Trials
0
Interventional, condition-specific
Researchers
969
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare form of chronic cutaneous lupus erythematosus characterized by recurrent, indurated, erythematous plaques and subcutaneous nodules with normal overlying epidermis, occurring predominantly on the face, upper arms, trunk, buttocks, and thighs. The lesions can ulcerate and lead to scarring. Histological findings include lobular lymphocytic panniculitis, hyaline fat necrosis, mucin deposition, and calcification. The condition may be associated with discoid or systemic lupus erythematosus.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019561
- MeSH:D015435
- UMLS:C0030327
- NCIT:C82884
Additional Mondo synonyms (3)
lupus erythematosus profundus · lupus panniculitis · lupus profundus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,048 matched papers (554 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 12 for broader category panniculitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,048
1,048 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,048 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
554 in the last 10 years · low confidence
Phrase hits: 1,047 · MeSH hits: 2
Who's working on it?
969
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Chong BF6 papers · 2026
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Papers in Europe PMC - 02Werth VP5 papers · 2025
G. Sprow, BA, V.P. Werth, MD, Corporal Michael J. Crescenz VAMC, and Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. werth@pennmedicine.upenn.edu.
Papers in Europe PMC - 03Yamamoto T5 papers · 2024
Department of Dermatology, Fukushima Medical University, Fukushima, Japan.
Papers in Europe PMC - 04Cerroni L3 papers · 2025
Department of Dermatology, Dermatopathology Research Unit, Medical University of Graz, Graz, Austria.
Papers in Europe PMC - 05González-Cruz C3 papers · 2025
Servicio de Dermatología, Hospital Universitari Vall d'Hebron, Barcelona, España. Electronic address: carlos.gonzalez.cruz@hotmail.com.
Papers in Europe PMC - 06Kalomeris T3 papers · 2024
Taylor Kalomeris, DO Department of Pathology and Laboratory Medicine, New York-Presbyterian/Weill Cornell Medicine, New York, New York.
Papers in Europe PMC - 07Lu Q3 papers · 2026
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China qianlu5860@pumcderm.cams.cn.
Papers in Europe PMC - 08Magro CM3 papers · 2024
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA. Electronic address: cym2003@med.cornell.edu.
Papers in Europe PMC - 09Mori T3 papers · 2023
Departamento de Dermatología, Fukushima Medical University, Fukushima, Japón. Electronic address: mtatsu@fmu.ac.jp.
Papers in Europe PMC - 10Singh S3 papers · 2026
Rheumatology, University of Florida College of Medicine - Jacksonville, Jacksonville, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 12 trials are registered for panniculitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
12 interventional trials matched panniculitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: panniculitis
12
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07691450·NOT YET RECRUITING·Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
Conditions: Recurrent Anaplastic Large Cell Lymphoma · Recurrent Enteropathy-Associated T-Cell Lymphoma · Recurrent Follicular Helper T-Cell Lymphoma · Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type·Matched via name phrase
- NCT05475925·RECRUITING·A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Conditions: LGLL - Large Granular Lymphocytic Leukemia · Primary Cutaneous Gamma-Delta T-Cell Lymphoma · Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma · Hepatosplenic T-cell Lymphoma·Matched via name phrase
- NCT06838988·RECRUITING·Ultrasonographic Patterns and Pathological Correlation in the Diagnosis of Subcutaneous Nodules
Conditions: Nodules · Ultrasonography · Panniculitis·Matched via name phrase
- NCT07055477·RECRUITING·A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Conditions: Relapsed and/or Refractory Mature T Cell Malignancy · Peripheral T-Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Anaplastic Large Cell Lymphoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Lupus erythematosus panniculitis" OR "Lupus erythematosus profundus" OR "lupus panniculitis" OR "lupus profundus"
MeSH descriptor terms unioned into the query: Panniculitis, Lupus Erythematosus
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Lupus erythematosus panniculitis" OR "Lupus erythematosus profundus" OR "lupus panniculitis" OR "lupus profundus" OR "Panniculitis, Lupus Erythematosus"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"panniculitis"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1048) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T03:42:56.619Z